

27 June 2022

**Cizzle Biotechnology Holdings Plc**

("Cizzle Biotechnology" or the "Company")

**Result of AGM**

Cizzle Biotechnology, the UK based diagnostics developer, announces that at the Annual General Meeting ("AGM") of the Company held earlier today, all resolutions were voted on by a poll and were passed.

The votes cast in respect of the resolutions were as follows:

Resolution	For		Against		Votes withheld
	Total votes	%	Total votes	%	
1. That the Annual Report and Accounts for the year ended 31 December 2021 be received	55,444,064	100.00%	0	0.00%	30,000
2. For the approval of the Directors' Remuneration Policy which takes effect immediately after the end of the AGM	55,297,384	94.84%	90,139	0.16%	86,541
3. For the approval of the Remuneration Report set out on pages 21 to 26 of the annual report	55,297,584	99.84%	90,139	0.16%	86,341
4. For the re-election of John Treacy as a director of the Company	55,444,064	100.00%	0	0.00%	30,000
5. For the re-election of Nigel Lee as a director of the Company	55,444,064	100.00%	0	0.00%	30,000

6. For the re-election of Dawn Coverley as a director of the Company	55,409,864	99.94%	34,200	0.06%	30,000
7. For the re-appointment of PKF Littlejohn LLP as auditors to the Company.	55,444,064	100.00%	0	0.00%	30,000
8. Authorises the Directors to determine the remuneration of the auditors	55,388,125	99.90%	55,939	0.10%	30,000
9. Authorises the directors to allot shares pursuant to Section 551 of the Companies Act 2006	54,796,868	99.89%	58,814	0.11%	618,382
10. Authorises the directors to allot equity securities pursuant to Section 570 of the Companies Act 2006	52,358,832	94.62%	2,979,293	5.38%	135,939
11. For the approval of the adoption of the new Articles of Association	55,444,064	100.00%	0	0.00%	30,000
12. For the calling of general meetings on not less than 14 clear days' notice	55,444,064	100.00%	0	0.00%	30,000

**Enquiries:**

**Cizzle Biotechnology Holdings plc**  
Allan Syms (Executive Chairman)

Via IFC Advisory

**Allenby Capital Limited**

John Depasquale  
Alex Brearley

+44(0) 20 33285656

**Novum Securities Limited**

Colin Rowbury  
Jon Bellis

+44(0) 20 7399 9400

**IFC Advisory Limited**

Tim Metcalfe  
Florence Chandler

+44(0) 20 3934 6630

[cizzle@investor-focus.co.uk](mailto:cizzle@investor-focus.co.uk)

**Notes to Editors:****About Cizzle Biotechnology**

Cizzle Biotechnology is developing a blood test for the early detection of lung cancer. Cizzle Biotechnology is a spin-out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.

For more information, please see <https://cizzlebiotechnology.com>

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.